Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Accumulated Expenses: 2009-2015

Historic Other Accumulated Expenses for Madrigal Pharmaceuticals (MDGL) over the last 7 years, with Sep 2015 value amounting to $5.0 million.

  • Madrigal Pharmaceuticals' Other Accumulated Expenses rose 1.06% to $5.0 million in Q3 2015 from the same period last year, while for Sep 2015 it was $5.0 million, marking a year-over-year increase of 1.06%. This contributed to the annual value of $6.2 million for FY2014, which is 8.03% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $5.0 million for Q3 2015, which was down 8.72% from $5.5 million recorded in Q2 2015.
  • Madrigal Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $6.2 million for Q4 2014, and its period low was $2.2 million during Q1 2011.
  • Its 3-year average for Other Accumulated Expenses is $4.9 million, with a median of $5.0 million in 2015.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Other Accumulated Expenses slumped by 33.29% in 2011 and then surged by 67.84% in 2014.
  • Over the past 5 years, Madrigal Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $4.6 million in 2011, then increased by 11.60% to $5.1 million in 2012, then increased by 11.53% to $5.7 million in 2013, then climbed by 8.03% to $6.2 million in 2014, then rose by 1.06% to $5.0 million in 2015.
  • Its Other Accumulated Expenses stands at $5.0 million for Q3 2015, versus $5.5 million for Q2 2015 and $5.4 million for Q1 2015.